Belite Bio reported topline success from its 104-subject Phase 3 DRAGON trial: tinlarebant produced a statistically significant 36% reduction in the growth rate of retinal lesions versus placebo in adolescents with Stargardt disease type 1 (STGD1). The company framed the result as the first positive pivotal data for an STGD1 therapy, and said it will pursue regulatory filings in the U.S. and other markets. Tinlarebant lowers serum retinol‑binding protein 4 to reduce toxic vitamin A derivatives in the eye; the result could establish the first approved treatment for a progressive inherited retinal disease that currently lacks options.